Sector News

UDG Healthcare in acquisition of US-based MicroMass Communications

September 25, 2017
Life sciences

Irish healthcare services provider UDG Healthcare has announced the acquisition of MicroMass Communications, a US-based healthcare communications agency, for a total consideration of up to $75.8m (€63.8m).

MicroMass, which specialises in behavioural change, is being acquired for an initial consideration of $63.8m, with an additional consideration of up to $12m payable over the next three years, based on the achievement of agreed profit targets.

The existing management team, who have been with the business for more than 10 years, will remain with the business post acquisition.

“MicroMass provides the group with the ability to strengthen Ashfield’s presence and capabilities in the US market, whilst also providing us with a platform to expand into the high growth areas of behavioural change and direct patient engagement,” Brendan McAtamney, CEO of UDG, said.

MicroMass, which employs more than 100 people, generates the majority of its revenue from patient engagement and support programmes, with the remainder coming from HCP (healthcare professional) focused work.

The company’s behavioural change and patient support and adherence services are highly complementary to the existing services provided by both the Ashfield Communications and Commercial and Clinical businesses, a statement from UDG said.

“We are excited to be joining the team at UDG Healthcare. Being part of a global business creates new opportunities for continued growth and new collaborations within UDG, which will enable us to develop more comprehensive solutions for our clients,” Alyson Connor, MicroMass president, said.

UDG has now committed more than $275m to acquisitions this financial year, in line with its strategy of expanding into higher growth, higher margin areas, through acquisitions.

In July the company purchased Cambridge BioMarketing, a firm that focuses on orphan and rare disease drug launches, in what was its fifth acquisition in its financial year.

By Ellie Donnelly

Source: Independent.ie

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).